Clinical Trial Update: A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study of Noscapine HCl (CB3304) in patients with relapsed or refractory multiple myeloma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Noscapine HCl (CB3304) (Noscapine HCl)

Snippet

Sponsor: Cougar Biotechnology, Inc. | Conditions: Refractory Multiple Myeloma | Phase 1 | Status: TERMINATED